secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001193125-23-004115
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix Therapeutics outlines 2023 clinical milestones for BTK degraders and CBL-B inhibitor at JPM Conference
--------------------------------------------------------------------------------

- NX-2127 BTK degrader: clinical update and regulatory strategy in H2 2023.
- NX-5948 BTK degrader: initial Phase 1a data and dose for expansion in H2 2023.
- NX-1607 CBL-B inhibitor: Phase 1a data and dose for expansion in H2 2023.
- Cash, equivalents and marketable securities of $413.6M as of Aug 2022; runway into Q4 2024.
- Raised $115M in 2022; expects to select new development candidate in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000119312523004115/0001193125-23-004115-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000119312523004115/d426013d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-004115

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer